NCT06700603View on ClinicalTrials.gov

Second-line Irinotecan Liposome Combination Regimen for Irinotecan-treated Pancreatic Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

November 20, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
Pancreatic Cancer
Interventions
DRUG

Irinotecan liposome (Nal-IRI) in combination with 5-FU/sodium levofolinate

Irinotecan liposome (Nal-IRI) in combination with 5-FU/sodium levofolinate，Every 2 weeks until disease progression or patient develops intolerable toxicity

All Listed Sponsors
lead

Rui-hua Xu, MD, PhD

OTHER

NCT06700603 - Second-line Irinotecan Liposome Combination Regimen for Irinotecan-treated Pancreatic Cancer | Biotech Hunter | Biotech Hunter